References
- Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J. Clin.57(1), 43–66 (2007).
- Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics21(18), 1315–1330 (2003).
- Stein JP, Lieskovsky G, Cote R et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients. J. Clin. Oncol.19(3), 666–675 (2001).
- Lotan Y, Gupta A, Shariat SF et al. Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy. J. Clin. Oncol.23(27), 6533–6539 (2005).
- Messing EM, Young TB, Hunt VB et al. Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with standard clinical presentations. Urology45(3), 387–396; discussion 396–397 (1995).
- Messing EM, Madeb R, Young T et al. Long-term outcome of hematuria home screening for bladder cancer in men. Cancer107(9), 2173–2179 (2006).
- Lotan Y, Roehrborn CG. Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. Urology61(1), 109–118 (2003).
- Benoit RM, Gronberg H, Naslund MJ. A quantitative analysis of the costs and benefits of prostate cancer screening. Prostate Cancer Prostatic Dis.4(3), 138–145 (2001).
- Pignone M, Rich M, Teutsch SM, Berg AO, Lohr KN. Screening for colorectal cancer in adults at average risk: a summary of the evidence for the U.S. Preventive Services Task Force. Ann. Intern. Med.137(2), 132–141 (2002).
- Redaelli A, Cranor CW, Okano GJ, Reese PR. Screening, prevention and socioeconomic costs associated with the treatment of colorectal cancer. Pharmacoeconomics21(17), 1213–1238 (2003).
- Lindfors KK, Rosenquist CJ. The cost–effectiveness of mammographic screening strategies. JAMA274(11), 881–884 (1995).
- Shen Y, Parmigiani G. A model-based comparison of breast cancer screening strategies: mammograms and clinical breast examinations. Cancer Epidemiol. Biomarkers Prev.14(2), 529–532 (2005).
- Peto J, Gilham C, Fletcher O, Matthews FE. The cervical cancer epidemic that screening has prevented in the UK. Lancet364(9430), 249–256 (2004).
- Beinfeld MT, Wittenberg E, Gazelle GS. Cost–effectiveness of whole-body CT screening. Radiology234(2), 415–422 (2005).
- Lotan Y, Svatek RS, Sagalowsky AI. Should we screen for bladder cancer in a high-risk population? A cost per life-year saved analysis. Cancer107(5), 982–990 (2006).
- Svatek RS, Sagalowsky AI, Lotan Y. Economic impact of screening for bladder cancer using bladder tumor markers: a decision analysis. Urol. Oncol.24(4), 338–343 (2006).
- Wu XR. Urothelial tumorigenesis: a tale of divergent pathways. Nat. Rev. Cancer5(9), 713–725 (2005).
- Messing EM, Vaillancourt A. Hematuria screening for bladder cancer. J. Occup. Med.32(9), 838–845 (1990).
Websites
- American College of Surgeons. Commission on Cancer National Cancer Database (Accessed 7 September 2005) www.facs.org/cancer/ncdb/index.html
- Surveillance, Epidemiology, and End Results (SEER) Program SEER*Stat Database: Incidence – SEER 9 Regs Public-Use, Nov 2004 Sub (1973–2002), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2005, based on the November 2004 submission www.seer.cancer.gov